Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

Kenneth H. Shain, MD PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Qi Zhang, PhD, Oliver Hampton, Constantine Logothetis, MD, Christian Argueta, PhD, Yosef Landesman, PhD, Ariosto Siqueira Silva, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140485

Published: 2020

Journal Articles

CRISPR/Cas9 Chemogenetic Profiling Identifies Candidate Biomarker Genes That Modulate Sensitivity to Selinexor

Bert Kwanten, MSc, Yosef Landesman, PhD, Dirk Daelemans

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-141785

Published: 2020

Journal Articles

A Six-Protein Activity Signature Defines Favorable Response to Selinexor Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Christopher J. Walker, PhD, Yao Shen, PhD, Mariano Alvarez, PhD, Hua Chang, PhD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Andrea Califano, Dr, Yosef Landesman, PhD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-142004

Published: 2020

Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Shambavi Richard, MD, Ajai Chari, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, Hua Chang, PhD, Yosef Landesman, PhD, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Sebastian Grosicki, MD PhD, Paul G. Richardson, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137154

Published: 2020

Journal Articles

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Alessandro Lagana, PhD, Sherry Bhalla, Adolfo Aleman, Anna Huo-Chang Mei, MS, Violetta Leshchenko, PhD, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepu Madduri, MD, Joshua R Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3101.

https://doi.org/10.1182/blood-2019-130753

Published: 2019

Journal Articles

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Alessandro Lagana, PhD, Seongjee Park, Donna Edwards, Violetta Leshchenko, PhD, Marsha Crochiere, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Joshua Richter, Ajai Chari, MD, Hearn Jay Cho, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2018) 132 (Supplement 1): 3216.

https://doi.org/10.1182/blood-2018-99-116500

Published: 2018

Journal Articles

XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IκB

Y. Lynn Wang, MD PhD, Mei Ming, PhD, Bingqing Xie, Madina Sukhanova, Weige Wang, MD, Sabah Kadri, PhD, Shruti Sharma, Jimmy Lee, Sharon Shacham, PhD MBA, Yosef Landesman, PhD, Natalia Maltsev, Pin Lu, PhD

Blood (2017) 130 (Supplement 1): 3837.

https://doi.org/10.1182/blood.V130.Suppl_1.3837.3837

Published: 2017

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Marsha L. Crochiere, PhD, Stefan Hannus, PhD, Kerrin Hansen, Frank Becker, PhD, Erkan Baloglu, PhD, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 1563.

https://doi.org/10.1182/blood.V128.22.1563.1563

Published: 2016

Journal Articles

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Trinayan Kashyap, MS, Boris Klebanov, MA, MS, Christian Argueta, PhD, Margaret S. Lee, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD

Blood (2016) 128 (22): 5660.

https://doi.org/10.1182/blood.V128.22.5660.5660

Published: 2016

Journal Articles

Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance

Maria Todaro, PhD, Valentina Griggio, Ms, Candida Vitale, MD, Chiara Salvetti, MD, Chiara Riganti, MD, Mario Boccadoro, MD, Yosef Landesman, PhD, Marta Coscia, MD PhD

Blood (2016) 128 (22): 3210.

https://doi.org/10.1182/blood.V128.22.3210.3210

Published: 2016

Journal Articles

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Joel G Turner, PhD, Trinayan Kashyap, MS, Jana L Dawson, BS, Juan A Gomez, BS, Alexis Bauer, BS, Steven Grant, MD, Yun Dai, PhD, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Yosef Landesman, PhD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 3299.

https://doi.org/10.1182/blood.V128.22.3299.3299

Published: 2016

Journal Articles

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T Cell Effector Function in Mice: Implications for Combination with Immunotherapy

Paul M Tyler, Mariah M Servos, Boris Klebanov, Trinayan Kashyap, MS, Sharon Shacham, PhD MBA, Yosef Landesman, PhD, Michael Dougan, Stephanie K Dougan

Blood (2016) 128 (22): 2525.

https://doi.org/10.1182/blood.V128.22.2525.2525

Published: 2016

Journal Articles

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

Trinayan Kashyap, MS, Irfana Muqbil, Amro Aboukameel, Boris Klebanov, MA, MS, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, William Senapedis, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 4131.

https://doi.org/10.1182/blood.V128.22.4131.4131

Published: 2016

Journal Articles

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Xiaorong Gu, PhD, Reda Z. Mahfouz, MD, PhD, Quteba Ebrahem, Francis Enane, Tomas Radivoyevitch, PhD, Michael J. Clemente, M.S., Bartlomiej P Przychodzen, MSc, Zhenbo Hu, MD PhD, Ramesh Balusu, PhD, Claudiu V. Cotta, MD, David N. Wald, MDPhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, Jaroslaw P Maciejewski, MD PhD FACP, Yogenthiran Saunthararajah, MD

Blood (2016) 128 (22): 444.

https://doi.org/10.1182/blood.V128.22.444.444

Published: 2016

Journal Articles

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Fabrice Jardin, MD PhD, Anais Pujals, PhD, Laura Pelletier, PhD, Elodie Bohers, PhD, Vincent Camus, Sylvain Mareschal, Sydney Dubois, Marlène Ochman, MD, Francois Lemonnier, MD, Pierre-Julien Viailly, Philippe Bertrand, PhD, Catherine Maingonnat, Alexandra Traverse-Glehen, Philippe Gaulard, MD PhD, Diane Damotte, MD PhD, Richard Delarue, MD, Corinne Haioun, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD, Christian Argueta, PhD, Gilles Andre Salles, MD PhD, Jean-Philippe Jais, MD PhD, Martin Figeac, PhD, Christiane Copie-Bergman, MD PhD, Thierry Molina, Jean-Michel Picquenot, PhD, Marie Cornic, Thierry Fest, MD PhD, Noel Milpied, Emilie Lemasle, MD, Aspasia Stamatoullas, MD, Peter Moeller, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Christer Sundstrom, MD PhD, Christian Bastard, MD PhD, Hervé Tilly, MD PhD, Karen Leroy, MD PhD

Blood (2015) 126 (23): 129.

https://doi.org/10.1182/blood.V126.23.129.129

Published: 2015

Journal Articles

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML

Jeffrey E Rubnitz, MD PhD, Ronda Kaufman, PhD, Raul C. Ribeiro, MD, Boris Klebanov, MA, MS, Joel Ellis, PhD, Yosef Landesman, PhD, Hagop Youssoufian, MD, Tami Rashal, MD, Sharon Shacham

Blood (2015) 126 (23): 1345.

https://doi.org/10.1182/blood.V126.23.1345.1345

Published: 2015

Journal Articles

Development of a Pharmacodynamic Assay for XPO1 Occupancy Using Fluorescence Cross Correlation Spectroscopy (FCCS)

Marsha L. Crochiere, PhD, Stefan Hannus, PhD, Kerrin Hansen, Frank Becker, PhD, Joel Ellis, PhD, Margaret S. Lee, PhD, Yosef Landesman, PhD

Blood (2015) 126 (23): 2487.

https://doi.org/10.1182/blood.V126.23.2487.2487

Published: 2015

Journal Articles

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Shows Synergistic Anti-Tumor Activity in Combination with Dexamethasone Characterized By Specific Pattern of Gene Expression in Multiple Myeloma (MM)

Trinayan Kashyap, MS, Boris Klebanov, MA, MS, Margaret S. Lee, PhD, Yosef Landesman, PhD

Blood (2015) 126 (23): 3683.

https://doi.org/10.1182/blood.V126.23.3683.3683

Published: 2015

Journal Articles

Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples

Paul Brent Ferrell, Jr., MD, William Senapedis, PhD, Alexander Cook, Erkan Baloglu, PhD, Yosef Landesman, PhD, Jonathan Michael Irish, PhD, Michael R. Savona, MD

Blood (2015) 126 (23): 3686.

https://doi.org/10.1182/blood.V126.23.3686.3686

Published: 2015

NARROW

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

CRISPR/Cas9 Chemogenetic Profiling Identifies Candidate Biomarker Genes That Modulate Sensitivity to Selinexor

A Six-Protein Activity Signature Defines Favorable Response to Selinexor Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IκB

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T Cell Effector Function in Mice: Implications for Combination with Immunotherapy

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Recurrent Mutations of the Exportin 1 Gene ( XPO1 ) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML

Development of a Pharmacodynamic Assay for XPO1 Occupancy Using Fluorescence Cross Correlation Spectroscopy (FCCS)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) Compound, Shows Synergistic Anti-Tumor Activity in Combination with Dexamethasone Characterized By Specific Pattern of Gene Expression in Multiple Myeloma (MM)

Dissecting Signaling Network Responses to PAK4 Allosteric Modulators (PAMs) in Cell Subsets within Primary Human Acute Myeloid Leukemia Samples

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only